Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 27, 2025 • 9:00 AM ET

Date/Time Source News Release
04/09/2025 07:45 AM EDT Newsfile Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
04/03/2025 07:45 AM EDT Newsfile Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
03/31/2025 04:00 PM EDT Newsfile Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
03/10/2025 07:45 AM EDT Newsfile American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
03/05/2025 07:45 AM EST Newsfile Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
02/26/2025 07:45 AM EST Newsfile Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
02/20/2025 07:45 AM EST Newsfile Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
02/03/2025 07:45 AM EST Newsfile Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
01/22/2025 07:00 AM EST Newsfile Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
01/21/2025 04:15 PM EST Newsfile Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Page

Additional News

As of April 27, 2025 • 9:00 AM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.